Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625553 | 0.90 | CA2 (0.55) | CA2CA1FFAR1CA9 | |
| SCHEMBL8007555 | 0.85 | CA2 (0.54) | CA2CA1FFAR1CA9 | |
| SCHEMBL8077441 | 0.84 | CA2 (0.53) | CA2CA1FFAR1CA9 | |
| SCHEMBL8441263 | 0.84 | CA2 (0.53) | CA2CA1FFAR1CA9 | |
| SCHEMBL16394942 | 0.81 | CA2 (0.54) | CA2CA1 | |
| SCHEMBL6616820 | 0.81 | KDM4E (0.45) | FDFT1MMP12MMP13HRH4HRH3 | |
| SCHEMBL17168321 | 0.80 | MITF (0.54) | CA2CA1 | |
| SCHEMBL17708496 | 0.80 | CA2 (0.52) | CA2CA1CA9 | |
| SCHEMBL6586107 | 0.80 | CA2 (0.68) | CA2CA1CA9 | |
| SCHEMBL17168168 | 0.79 | CA2 (0.51) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321045-B2 | Catalyst and process for synthesising the same | THE UNIVERSITY OF WARWICK (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | THE UNIVERSITY OF WARWICK (GB) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | CBR3, SPR, RNF5 | CA2 3693/4885CA1 4151/4885FDFT1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.